Stay updated on Eribulin + Pembrolizumab in Soft Tissue Sarcomas Clinical Trial
Sign up to get notified when there's something new on the Eribulin + Pembrolizumab in Soft Tissue Sarcomas Clinical Trial page.

Latest updates to the Eribulin + Pembrolizumab in Soft Tissue Sarcomas Clinical Trial page
- Check3 days agoChange DetectedThe page footer has an updated software/UI revision label from v3.5.2 to v3.5.3.SummaryDifference0.1%

- Check10 days agoChange DetectedRevision label updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check32 days agoChange DetectedAdded the MeSH term Malignant fibrous histiocytoma to the study's indexing terms.SummaryDifference0.1%

- Check39 days agoChange DetectedRevision: v3.5.0 is now displayed, replacing the previous Revision: v3.4.3.SummaryDifference0.1%

- Check53 days agoChange DetectedRevision: v3.4.3 added; Revision: v3.4.2 removed.SummaryDifference0.1%

- Check75 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2; no study content or eligibility details were altered. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Eribulin + Pembrolizumab in Soft Tissue Sarcomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Eribulin + Pembrolizumab in Soft Tissue Sarcomas Clinical Trial page.